IRVINE, CA / ACCESSWIRE / April 25, 2022 / ORHub, Inc. (OTC PINK:ORHB) announced today it has purchased 100% of the equity interest and assets of PUR Biologics, LLC.
ORHub will enter the global medical device market, expected to reach $445.1 billion by 2026. With top categories in the USA including Hip, Knee, & Spine, reaching $75 billion, ORHub will utilize PUR's proprietary technologies to regenerate cartilage, mitigate pain, and address the biological causes of degenerative disc disease and osteoarthritis of joints.
"We plan to offer improved treatments for age-related joint pain and the degeneration of cartilage in orthopedic indications. Technologies like PUR's can enable new ways to address the underlying cause of undesired inflammation and pain signals, while igniting our body's natural healing capabilities," shared CJ Wiggins - Founder, Executive Chairman, President & CEO for ORHub. "We are excited about this acquisition and the opportunity to advance autologous cell and cellular derived therapeutics for osteoarthritis and degenerative disc disease."
"PUR Biologics has cultivated innovative technologies, in addition to our full line of bone regeneration products currently on the market. We have identified and secured intellectual property that will finally address major gaps in medical treatment. ORHub is the ideal acquisition partner, with both the necessary science and business structure to take our technologies to the global market," explained Ryan Fernan, former CEO of PUR Biologics.
With this addition to ORHub, plans are being made to update the corporate branding and ticker symbol to encompass its Digital Technology and Regenerative Therapeutic division as it continues its preparations for an audit and up- listing.
